Literature DB >> 3144656

The response of apomorphine administered into the accumbens in rats with bilateral lesions of the nucleus accumbens, induced with 6-hydroxydopamine.

F S Radhakishun1, G Wolterink, J M van Ree.   

Abstract

Bilateral lesions of the nucleus accumbens, induced with 6-hydroxydopamine, reduced motor activity and produced a 20-35% depletion of the concentrations of dopamine (DA) and its main metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Small doses of apomorphine (1-10 ng), injected into the nucleus accumbens of sham-lesioned rats, decreased motor activity, while larger doses (1-10 micrograms) produced hyperactivity. In rats lesioned with 6-hydroxydopamine, apomorphine caused hyperactivity only, and this apomorphine-induced response was more pronounced than in sham-lesioned rats. Large doses of apomorphine decreased, only in sham-lesioned animals, the levels of DOPAC and HVA. These data suggest that the apomorphine-induced hypomotility is mediated by presynaptically located DA receptor systems in the nucleus accumbens, whereas the apomorphine-induced hypermotility is likely to be mediated by postsynaptically located DA receptor systems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144656     DOI: 10.1016/0028-3908(88)90005-6

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  2 in total

1.  Comparison of the effects of dopamine agonists on self-stimulation of the hypothalamus with lesioning of mesolimbic brain structures in rats reared in conditions of social isolation.

Authors:  G N Panchenko; A A Lebedev; P D Shabanov
Journal:  Neurosci Behav Physiol       Date:  1998 Mar-Apr

2.  The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.

Authors:  Mark J Millan; Laetitia Seguin; Alain Gobert; Didier Cussac; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.